|
A more recent version of this article appeared on January 6, 2006
Papers In Press, published online ahead of print October 24, 2005
J. Biol. Chem, 10.1074/jbc.M508455200
Submitted on August 2, 2005
Revised on October 5, 2005
Accepted on October 24, 2005
Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor
Xin Liu, Adrienne Clements, Kehao Zhao, and Ronen Marmorstein
The Wistar Institute, Philadelphia, PA 19104
Corresponding Author: marmor{at}wistar.org
The E7 oncoprotein from human papillomavirus (HPV) mediates cell transformation, in part, by binding to the human pRb tumor suppressor protein and E2F transcription factors, resulting in the dissociation of pRb from E2F transcription factors and the premature cell progression into the S-phase of the cell cycle. This activity is mediated by the LXCXE motif and the CR3 zinc-binding domain of the E7 protein. In this study we report the X-ray crystal structure of the CR3 region of HPV E7 and a structure-based mutational analysis to investigate its mode of pRb and E2F-binding and E2F displacement from pRb. The structure reveals a novel zinc bound E7-CR3 obligate homodimer that contains 2 surface patches of sequence conservation. Mutation of residues within these patches reveals that one patch is required for pRb-binding while the other is required for E2F-binding. We also show that both E7-mediated interactions are required to disrupt pRb/E2F complexes. Based on these studies we present a mechanistic model for how E7 displaces E2F from pRb. Since the CR3 region of HPV E7 has no detectable homology to other human proteins, the structure-function studies presented here provides an avenue for developing small molecule compounds that inhibit HPV-E7-mediated cell transformation.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Burniat, L. Jin, V. Detours, N. Driessens, J.-C. Goffard, M. Santoro, J. Rothstein, J. E. Dumont, F. Miot, and B. Corvilain
Gene Expression in RET/PTC3 and E7 Transgenic Mouse Thyroids: RET/PTC3 But Not E7 Tumors Are Partial and Transient Models of Human Papillary Thyroid Cancers
Endocrinology,
October 1, 2008;
149(10):
5107 - 5117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. McLaughlin-Drubin, K.-W. Huh, and K. Munger
Human Papillomavirus Type 16 E7 Oncoprotein Associates with E2F6
J. Virol.,
September 1, 2008;
82(17):
8695 - 8705.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Darnell, W. A. Schroder, T. M. Antalis, E. Lambley, L. Major, J. Gardner, G. Birrell, A. Cid-Arregui, and A. Suhrbier
Human Papillomavirus E7 Requires the Protease Calpain to Degrade the Retinoblastoma Protein
J. Biol. Chem.,
December 28, 2007;
282(52):
37492 - 37500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Liu and R. Marmorstein
Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor
Genes & Dev.,
November 1, 2007;
21(21):
2711 - 2716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Liu and R. Marmorstein
When viral oncoprotein meets tumor suppressor: a structural view
Genes & Dev.,
September 1, 2006;
20(17):
2332 - 2337.
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|